EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalised approach

Sacha Spelier, Karin de Winter-de Groot, Natascha Keijzer-Nieuwenhuijze, Yves Liem, Kors van der Ent, Jeffrey Beekman, Lieke S Kamphuis

European Respiratory Journal · 2024-01 · 63 (1) · 2300770

DOI: 10.1183/13993003.00770-2023 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Respiratory Journal, online erschienen am 19.10.2023. Verfasst von Sacha Spelier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Simvastatin, Aminopyridines, Benzamides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Emily's Entourage.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Highly effective cystic fibrosis transmembrane conductance regulator (CFTR) protein-targeting modulator therapies (HEMTs) facilitate strong clinical improvements in a large proportion of people with CF (PwCF) [1, 2]. More specifically, the EMA and FDA approved combination of the CFTR modulators elexacaftor/tezacaftor/ivacaftor (ETI) for PwCF with at least one F508del allele, whilst the FDA extended eligibility for several rare genotypes [3, 4]. However, 10–15% of PwCF carry CFTR mutations that are unresponsive to HEMTs as monotherapy [1]. Furthermore, some pwCF suffer from HEMT intolerance or HEMTs are not accessible due to practical challenges such as lack of access due to high costs or legislation and approval challenges. Consequently, the focus in the CF research field has shifted towards filling the unmet clinical need for the PwCF that will not benefit from HEMTs. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic Fibrosis Transmembrane Conductance RegulatorSimvastatinAminopyridinesBenzamidesHumansMutationOrganoidsCyclopropanes

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorRoflumilastSimvastatinCFTR protein, humanAminopyridinesBenzamidesCyclopropanes

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, Utrecht, The Netherlands.
  • Regenerative Medicine Utrecht, University Medical Center, Utrecht University, Utrecht, The Netherlands.
  • Department of Clinical Pharmacy, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, Utrecht, The Netherlands.
  • J. Beekman and L.S. Kamphuis contributed equally to this article as lead authors and supervised the work.
  • Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands l.kamphuis@erasmusmc.nl.

Förderung

  • Emily's Entourage

Zitieren

APA

Spelier, S., de Winter-de Groot, K., Keijzer-Nieuwenhuijze, N., Liem, Y., van der Ent, K., Beekman, J., & Kamphuis, L. S. (2024). Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalised approach. European Respiratory Journal, 63(1), 2300770. https://doi.org/10.1183/13993003.00770-2023

Vancouver

Spelier S, de Winter-de Groot K, Keijzer-Nieuwenhuijze N, Liem Y, van der Ent K, Beekman J, et al. Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalised approach. European Respiratory Journal. 2024;63(1):2300770. doi:10.1183/13993003.00770-2023

BibTeX
@article{Spelier2024,
  author = {Spelier, Sacha and de Winter-de Groot, Karin and Keijzer-Nieuwenhuijze, Natascha and Liem, Yves and van der Ent, Kors and Beekman, Jeffrey and Kamphuis, Lieke S},
  title = {Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: a personalised approach},
  journal = {European Respiratory Journal},
  year = {2024},
  volume = {63},
  number = {1},
  pages = {2300770},
  doi = {10.1183/13993003.00770-2023}
}
Kostenlos starten →